UniProt S6B291
Cetuximab Fab heavy chain (S6B291)
Cetuximab Fab heavy chain (UniProt S6B291): 53 experimental structures on GenesisL1, 6 ligands bound, 127 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- S6B291
- Protein
- Cetuximab Fab heavy chain
- Experimental structures
- 53
- Predicted models
- 0
- Ligands
- 6
- Pockets
- 127 · 18 records with a druggable one
Structures
53 records of S6B291 in the MolNFT archive: 53 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3MNW | Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived… | x-ray diffraction | B | — | — |
| 3MNW | Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a GP41 mper-derived… | x-ray diffraction | B | — | — |
| 3MNZ | Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived… | x-ray diffraction | B | — | — |
| 3MNZ | Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a GP41 mper-derived… | x-ray diffraction | B | — | — |
| 4EOW | Crystal structure of a disease-associated anti-human GM-CSF autoantibody MB007 | x-ray diffraction | H | — | — |
| 4EOW | Crystal structure of a disease-associated anti-human gm-csf autoantibody MB007 | x-ray diffraction | H | — | — |
| 4YDV | Structure of the antibody 7B2 that captures HIV-1 virions | x-ray diffraction | H, B | — | — |
| 4YDV | Structure of the antibody 7B2 that captures HIV-1 virions | x-ray diffraction | H, B | — | — |
| 5C7K | Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies… | x-ray diffraction | A | — | — |
| 5C7K | Crystal structure BG505 sosip GP140 HIV-1 env trimer bound to broadly neutralizing antibodies… | x-ray diffraction | A | — | — |
| 5CUS | Crystal Structure of sErbB3-Fab3379 Complex | x-ray diffraction | H, I, J, K | — | 11 (best 0.68) |
| 5CUS | Crystal structure of SERBB3-FAB3379 complex | x-ray diffraction | H, I, J, K | — | — |
| 5D9Q | Crystal structure of the BG505 sosip GP140 HIV-1 env trimer in complex with the broadly… | x-ray diffraction | H, F, N | — | — |
| 5VEB | Crystal structure of a Fab binding to extracellular domain 5 of Cadherin-6 | x-ray diffraction | A, H | — | — |
| 5VEB | Crystal structure of a Fab binding to extracellular domain 5 of cadherin-6 | x-ray diffraction | A, H | — | — |
| 5VIC | Crystal structure of anti-Zika antibody Z004 bound to DENV-1 Envelope protein DIII | x-ray diffraction | H | — | 4 (best 0.56) |
| 5VIC | Crystal structure of anti-zika antibody Z004 bound to denv-1 envelope protein diii | x-ray diffraction | H | — | — |
| 5VIG | Crystal structure of anti-zika antibody Z006 bound to zika virus envelope protein diii | x-ray diffraction | H, A | — | — |
| 5VIY | BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 | electron microscopy | H, J, K, M, O | NAG, BMA, MAN | 6 (best 0.77) |
| 5VIY | BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 | electron microscopy | H, J, K, M, O | NAG, BMA, MAN | — |
| 5VJ6 | BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 | electron microscopy | M, O, Q | — | 9 (best 0.81) |
| 5VJ6 | BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 | electron microscopy | M, O, Q | — | — |
| 5VL3 | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | x-ray diffraction | A, C, E, H | NAG | 15 (best 0.65) |
| 5VL3 | CD22 D1-D3 in complex with therapeutic Fab epratuzumab | x-ray diffraction | A, C, E, H | — | — |
| 5VOB | Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21 | x-ray diffraction | H | NAG | 3 (best 0.54) |
| 5VOB | Crystal structure of hcmv pentamer in complex with neutralizing antibody 8I21 | x-ray diffraction | H | NAG | — |
| 5VOC | Crystal structure of HCMV Pentamer in complex with neutralizing antibody 8I21 - Low resolution… | x-ray diffraction | H | NAG | 5 (best 0.57) |
| 5VOC | Crystal structure of hcmv pentamer in complex with neutralizing antibody 8I21 - low resolution… | x-ray diffraction | H | — | — |
| 5VOD | Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6 | x-ray diffraction | H | — | 3 (best 0.80) |
| 5VOD | Crystal structure of hcmv pentamer in complex with neutralizing antibody 9I6 | x-ray diffraction | H | — | — |
| 5VQM | Clostridium difficile TcdB-GTD bound to PA41 Fab | x-ray diffraction | H, D | — | 15 (best 0.84) |
| 5VQM | Clostridium difficile tcdb-gtd bound to PA41 Fab | x-ray diffraction | H, D | — | — |
| 6AU5 | Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant | x-ray diffraction | B, D | SO4 | 7 (best 0.72) |
| 6AU5 | Structure of cetuximab with aminoheptanoic acid-linked N-butylarginine meditope variant | x-ray diffraction | B, D | SO4 | — |
| 6AXP | Structure of cetuximab with aminoheptanoic acid-linked n-octylarginine meditope variant | x-ray diffraction | B, D | — | 10 (best 0.70) |
| 6AXP | Structure of cetuximab with aminoheptanoic acid-linked N-octylarginine meditope variant | x-ray diffraction | B, D | — | — |
| 6AYN | Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant | x-ray diffraction | B, D | — | 8 (best 0.74) |
| 6AYN | Structure of cetuximab with aminoheptanoic acid-linked N-(3- aminopropyl)-L-arginine meditope… | x-ray diffraction | B, D | — | — |
| 6AZK | Structure of cetuximab with aminoheptanoic acid-linked N-(3-hydroxypropyl)-L-arginine meditope… | x-ray diffraction | B, D | SO4 | 7 (best 0.73) |
| 6AZK | Structure of cetuximab with aminoheptanoic acid-linked N-(3- hydroxypropyl)-L-arginine meditope… | x-ray diffraction | B, D | SO4 | — |
| 6AZL | Structure of cetuximab with aminoheptanoic acid-linked N-carboxyethylarginine meditope variant | x-ray diffraction | B, D | — | 9 (best 0.73) |
| 6AZL | Structure of cetuximab with aminoheptanoic acid-linked N- carboxyethylarginine meditope variant | x-ray diffraction | B, D | — | — |
| 6B9Z | Trastuzumab Fab v3 | x-ray diffraction | B | — | 3 (best 0.65) |
| 6B9Z | Trastuzumab Fab V3 | x-ray diffraction | B | — | — |
| 6BAE | Trastuzumab Fab v3 in complex with CQFDLSTRRLKC | x-ray diffraction | B | — | 4 (best 0.65) |
| 6BAE | Trastuzumab Fab V3 in complex with cqfdlstrrlkc | x-ray diffraction | B | — | — |
| 6DCQ | Ectodomain of full length, wild type HIV-1 glycoprotein clone PC64M18C043 in complex with PGT151 Fab | electron microscopy | H, M | NAG, BMA, MAN, GAL, FUC | 4 (best 0.81) |
| 6DCQ | Ectodomain of full length, wild type HIV-1 glycoprotein clone PC64M18C043 in complex with PGT151 Fab | electron microscopy | H, M | NAG, BMA, GAL, FUC, MAN | — |
| 6OKP | B41 SOSIP.664 in complex with the silent-face antibody SF12 and V3-targeting antibody 10-1074 | electron microscopy | K, M, O, Q | NAG, BMA, MAN | 4 (best 0.77) |
| 6OKP | B41 SOSIP.664 in complex with the silent-face antibody SF12 and V3- targeting antibody 10-1074 | electron microscopy | K, M, O, Q | NAG, BMA, MAN | — |
| 6UTE | Crystal structure of Z032 Fab in complex with WNV EDIII | x-ray diffraction | C, A, E, G, I | — | — |
| 6UTE | Crystal structure of Z032 Fab in complex with wnv ediii | x-ray diffraction | C, A, E, G, I | — | — |
| 6VTU | DH717.1 Fab monomer in complex with MAN9 glycan | x-ray diffraction | H | MAN | — |
Ligands
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.